Abstract: We measured the plasma Interleukin-8 (IL-8) concentration in 240 patients with hematological diseases to investigate the role of IL-8 in hematologic disease. Significantly higher concentrations of IL-8 were observed in some patients with acute myelogenous leukemia (AML), acute lymphoid leukemia, and chronic myelogenous leukemia than in healthy control subjects. We found no correlation between the plasma IL-8 concentration and the number of white blood cells, neutrophils, or monocytes, and the serum C-reactive protein concentration. In one patient with acute monocytic leukemia (M5), the high plasma concentrations of IL-8 before treatment fell to control levels after chemotherapy along with a decrease in the number of leukemic monocytes. A positive correlation was observed between plasma IL-8 and IL-6, but not between the concentrations of other cytokines. High concentrations of IL-8 were detected in the supernatant of primary cultures of leukemia cells collected from 10 patients with AML. The reverse transcriptase-polymerase chain reaction showed that these cells expressed IL-8 mRNA. Leukemic cells might therefore be the main source of IL-8 in vivo under some circumstances. IL-8 might participate in the fundamental disease process of AML, in addition to its role in inflammation.
Introduction
Interleukin-8 (IL-8) is an important mediator of inflammation produced by monocytes/ macrophages, fibroblasts, and endothelial cells in response to stimulation by interleukin-1 (IL-1), tumor necrosis factor (TNF), or lipopolysaccharide (LPS )1-3). It has attracted attention as a new cytokine with a wide range of biologic activities, such as the facilitation of neutrophilic leukocyte chemotaxis1,2,4), the activation of leukocyte adhesion to the vascular endothelium, the up-regulation of the CD1lb/CD18 glycoprotein5-7, and the release of superoxide (O2-)8). 'Clinically, the role of IL-8 in inflammatory diseases, such as septicemia and various other infections9), adult respiratory distress syndrome10), psoriasis11,12), rheumatoid arthritis13-17), and gout18), has been studied, and a relationship between IL-8 and these diseases has been postulated. Recently, IL-8 production by various cancer cells and acute leukemia cells, especially acute monocytic leukemia (AMoL) cells, has been reported, and the complex metabolic dynamics of IL-8 are gradually being clarified19 -22) To elucidate the relationship between IL-8 and the pathogenesis of various hematologic AGACC-3') labeled with 32P. The relative expression levels of the IL-8 genes were evaluated with a densitometer (Model 300A. Molecular Dynamics, Sunnyvale, CA).
Results

Plasma concentrations of IL-8 in patients with hematologic diseases
The plasma concentrations of IL-8 in healthy normal subjects ranged from 12.3 to 31. pg/ml, indicating stable values (Fig. 1 ). Significant increases were noted in some patients with AML, ALL, and CML (Fig. 1) . Twenty-four patients who had no obvious inflammatory conditions or infectious disease were selected from among 77 patients with AML. Of these patients, higher concentrations were noted in patients with acute myelomonocytic leukemia (AMMoL) or AMoL (Fig. 2) . Correlation between laboratory data and the plasma concentrations of IL-8 Other clinical laboratory data in addition to IL-8 were investigated in most patients. No significant correlation was found between the plasma concentrations of IL-8 and other clinical laboratory data, such as white blood cell count, neutrophil count, monocyte count, blast count in peripheral blood, and serum C-reactive protein concentration (data not shown). Correlation between the plasma concentration o f IL-8 and that of other cytokines
Concentrations of other cytokines in addition to IL-8 were measured in the plasma of Table 1 ) on the left, and a patient with ALL on the right. Details are described in the results. in the plasma concentration of IL-8 were noted in some patients with AML, ALL, and CML.
Previous studies of plasma 1L-8 have been conducted, mainly with reference to infectious diseases. No studies, therefore, have been performed on the significance of IL-8 in hematologic diseases. In this study, the plasma concentration of IL-8 was measured at random in patients with hematologic diseases. In most patients, no significant correlation was noted between the plasma concentration of IL-8 and the white blood cell count, leukemia cell count, neutrophil count, monocyte count, or serum CRP concentration.
In a time-course study of a patient with leukemia, the plasma concentration of IL-8 was elevated during an episode of pneumonia (Fig. 4) .
The intensity of inflammation reflects the concentrations of the proinflammatory mediators IL-I and TNF at the site of inflammation.
In cells subjected to such inflammatory stimuli, IL-8 is synthesized as a chemical mediator of inflammation1-3).
Ostermann et al.9) have studied the dynamic changes in IL-8, IL-6, and TNF-a in serum during septic shock in leukopenic patients after intensive chemotherapy.
Concentrations of these cytokines reached their peaks within 48 hours of the onset of sepsis and were not correlated with the peripheral leukocyte count9). Infection after chemotherapy for acute leukemia is frequently encountered in clinical practice, especially in patients with severe leukopenia. Significantly 
